JPMorgan Chase & Co. Grows Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

JPMorgan Chase & Co. raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 4.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 101,750 shares of the company’s stock after buying an additional 4,236 shares during the period. JPMorgan Chase & Co. owned approximately 0.10% of Dyne Therapeutics worth $3,655,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. FMR LLC raised its holdings in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares in the last quarter. RTW Investments LP raised its stake in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after purchasing an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. increased its holdings in Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after buying an additional 331,940 shares during the last quarter. Finally, State Street Corp increased its holdings in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after buying an additional 440,890 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the transaction, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,071 shares of company stock worth $606,476 over the last quarter. 20.77% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $14.13 on Friday. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -3.97 and a beta of 1.16. Dyne Therapeutics, Inc. has a 1 year low of $14.03 and a 1 year high of $47.45. The business has a fifty day moving average of $25.63 and a 200-day moving average of $33.32.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.